Table 3.
Plasma 25-hydroxyvitamin D levels and colorectal cancer, overall and by tumour-infiltrating T-cell subset densitya
| Tertile 1 | Tertile 2 | Tertile 3 | P trend b | P heterogeneity c | ||
|---|---|---|---|---|---|---|
| Overalld | No. of cases/controls (151/301) | 64/106 | 50/99 | 37/96 | ||
| Crude OR (95% CI)e | 1 [Referent] | 0.83 (0.53-1.31) | 0.61 (0.36-1.02) | 0.06 | ||
| Multivariable OR (95% CI)f | 1 [Referent] | 0.84 (0.53-1.34) | 0.57 (0.33-0.99) | 0.05 | ||
| CD3+ cells | Low | |||||
| No. of cases/controls (65/129) | 22/50 | 24/41 | 19/38 | |||
| Crude OR (95% CI)e | 1 [Referent] | 1.33 (0.66-2.69) | 1.13 (0.50-2.57) | 0.69 | 0.05 | |
| Multivariable OR (95% CI)f | 1 [Referent] | 1.39 (0.67-2.85) | 1.07 (0.46-2.49) | 0.77 | 0.03 | |
| High | ||||||
| No. of cases/controls (86/172) | 42/56 | 26/58 | 18/58 | |||
| Crude OR (95% CI)e | 1 [Referent] | 0.59 (0.33-1.08) | 0.40 (0.20-0.79) | 0.008 | ||
| Multivariable OR (95% CI)f | 1 [Referent] | 0.57 (0.31-1.06) | 0.36 (0.17-0.75) | 0.006 | ||
| CD8+ cellsg | Low | |||||
| No. of cases/controls (73/145) | 28/51 | 23/52 | 22/42 | |||
| Crude OR (95% CI)e | 1 [Referent] | 0.83 (0.44-1.57) | 0.97 (0.46-2.02) | 0.86 | 0.19 | |
| Multivariable OR (95% CI)f | 1 [Referent] | 0.87 (0.45-1.69) | 0.97 (0.45-2.12) | 0.90 | 0.12 | |
| High | ||||||
| No. of cases/controls (76/152) | 34/56 | 27/45 | 15/51 | |||
| Crude OR (95% CI)e | 1 [Referent] | 0.92 (0.47-1.78) | 0.46 (0.21-0.98) | 0.05 | ||
| Multivariable OR (95% CI)f | 1 [Referent] | 0.86 (0.43-1.71) | 0.38 (0.16-0.88) | 0.03 | ||
| CD45RO+ cellsh | Low | |||||
| No. of cases/controls (77/153) | 31/60 | 25/46 | 21/47 | |||
| Crude OR (95% CI)e | 1 [Referent] | 1.04 (0.54-2.04) | 0.85 (0.41-1.75) | 0.66 | 0.20 | |
| Multivariable OR (95% CI)f | 1 [Referent] | 1.12 (0.56-2.24) | 0.86 (0.40-1.86) | 0.72 | 0.11 | |
| High | ||||||
| No. of cases/controls (73/146) | 33/47 | 25/51 | 15/48 | |||
| Crude OR (95% CI)e | 1 [Referent] | 0.72 (0.39-1.33) | 0.42 (0.20-0.91) | 0.03 | ||
| Multivariable OR (95% CI)f | 1 [Referent] | 0.66 (0.35-1.25) | 0.35 (0.16-0.80) | 0.01 | ||
| FOXP3+ cellsi | Low | |||||
| No. of cases/controls (69/138) | 31/52 | 20/46 | 18/40 | |||
| Crude OR (95% CI)e | 1 [Referent] | 0.71 (0.36-1.43) | 0.71 (0.33-1.55) | 0.37 | 0.74 | |
| Multivariable OR (95% CI)f | 1 [Referent] | 0.73 (0.35-1.52) | 0.64 (0.28-1.46) | 0.28 | 0.83 | |
| High | ||||||
| No. of cases/controls (77/153) | 31/52 | 28/49 | 18/52 | |||
| Crude OR (95% CI)e | 1 [Referent] | 0.97 (0.52-1.78) | 0.56 (0.27-1.14) | 0.13 | ||
| Multivariable OR (95% CI)f | 1 [Referent] | 0.96 (0.51-1.80) | 0.53 (0.25-1.13) | 0.12 | ||
Abbreviations: CI, confidence interval; OR, odds ratio.
Cutoff for low and high tumour-infiltrating T-cell subset density (cells/mm2): 244.97 for CD3+ cells, 236.65 for CD8+ cells, 376.97 for CD45RO+ cells, and 26.36 for FOXP3+ cells.
Test for trend was performed using the median value of each tertile of plasma 25-hydroxyvitamin D.
Comparing the risk of colorectal cancer associated with median value of each tertile of plasma 25-hydroxyvitamin D across subtypes of tumours.
Analysis was based on all cases having data on specific T-cells subsets and their matched controls.
Conditional logistic regression adjusted for the matching factors (sex, age and time of blood draw).
Adjusted for the same set of covariates as in Table 2.
Two cases with missing data on CD8+ cells and the matched four controls were excluded.
One case with missing data on CD45RO+ cells and the matched two controls were excluded.
Five cases with missing data on FOXP3+ cells and the matched 10 controls were excluded.